1ST Source Bank Has $2.06 Million Position in iShares Biotechnology ETF (NASDAQ:IBB)

1ST Source Bank lowered its holdings in iShares Biotechnology ETF (NASDAQ:IBBFree Report) by 3.9% during the third quarter, Holdings Channel.com reports. The firm owned 16,875 shares of the financial services provider’s stock after selling 681 shares during the period. 1ST Source Bank’s holdings in iShares Biotechnology ETF were worth $2,064,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of IBB. Moneta Group Investment Advisors LLC lifted its stake in iShares Biotechnology ETF by 131,598.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 4,469,845 shares of the financial services provider’s stock valued at $586,846,000 after buying an additional 4,466,451 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of iShares Biotechnology ETF by 159.9% in the first quarter. JPMorgan Chase & Co. now owns 1,966,359 shares of the financial services provider’s stock worth $253,975,000 after acquiring an additional 1,209,700 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of iShares Biotechnology ETF by 49.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,568,159 shares of the financial services provider’s stock worth $204,332,000 after acquiring an additional 521,820 shares in the last quarter. Citigroup Inc. increased its holdings in shares of iShares Biotechnology ETF by 17.7% in the second quarter. Citigroup Inc. now owns 2,354,882 shares of the financial services provider’s stock worth $298,976,000 after acquiring an additional 354,350 shares in the last quarter. Finally, ExodusPoint Capital Management LP bought a new stake in shares of iShares Biotechnology ETF in the second quarter worth about $31,285,000. Institutional investors and hedge funds own 69.61% of the company’s stock.

iShares Biotechnology ETF Stock Up 0.5 %

Shares of iShares Biotechnology ETF stock traded up $0.68 during trading hours on Monday, hitting $135.27. The company’s stock had a trading volume of 743,585 shares, compared to its average volume of 1,819,391. iShares Biotechnology ETF has a 12 month low of $111.83 and a 12 month high of $139.49. The stock has a 50 day moving average of $133.65 and a 200 day moving average of $126.63.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 27th. Shareholders of record on Thursday, December 21st were issued a $0.124 dividend. The ex-dividend date was Wednesday, December 20th. This represents a $0.50 annualized dividend and a dividend yield of 0.37%.

iShares Biotechnology ETF Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

See Also

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBFree Report).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.